Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05038800 · OUTCOME

Plasma Elimination Terminal Half-life (t½) of MK-0482

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) · Source last updated 2025-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Days
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Cycle 1: Pre-dose and Days 1, 2, 4, 8, and 15 post-dose. Cycle=21 days.

What was measured

t½ was defined as the time required to divide the MK-0482 plasma concentration by two after reaching pseudo-equilibrium. Blood samples were collected pre-dose and post-dose at designated timepoints to determine t½ of MK-0482.

Analysis population: All allocated participants who received at least 1 dose of study intervention, were compliant with the study procedures, and had available data from at least 1 treatment dose were analyzed.

Groups in this outcome

MK-0482 7.5 mg Q3W

Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \[Q3W\]) for up to 35 cycles (approximately 24 months).

MK-0482 25 mg Q3W

Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).

MK-0482 75 mg Q3W

Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).

MK-0482 225 mg Q3W

Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).

MK-0482 750 mg Q3W

Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MK-0482 7.5 mg Q3W1
MK-0482 25 mg Q3W1
MK-0482 75 mg Q3W5
MK-0482 225 mg Q3W3
MK-0482 750 mg Q3W2

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
MK-0482 7.5 mg Q3WNANANot reportedNot reportedNA = t½ and its corresponding geometric coefficient of variation were not calculated due to insufficient samples in the terminal phase to estimate lambda\_z.
MK-0482 25 mg Q3W2.46NANot reportedNot reportedNA = Geometric coefficient of variation values were not reported when N \< 2.
MK-0482 75 mg Q3W3.6973.9Not reportedNot reportedNot reported
MK-0482 225 mg Q3W11.234.7Not reportedNot reportedNot reported
MK-0482 750 mg Q3W11.223.6Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA = t½ and its corresponding geometric coefficient of variation were not calculated due to insufficient samples in the terminal phase to estimate lambda\_z.
        group Id
        OG000
        spread
        NA
        value
        NA
      2. comment
        NA = Geometric coefficient of variation values were not reported when N \< 2.
        group Id
        OG001
        spread
        NA
        value
        2.46
      3. group Id
        OG002
        spread
        73.9
        value
        3.69
      4. group Id
        OG003
        spread
        34.7
        value
        11.2
      5. group Id
        OG004
        spread
        23.6
        value
        11.2
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      5
    4. group Id
      OG003
      value
      3
    5. group Id
      OG004
      value
      2
    units
    Participants
description
t½ was defined as the time required to divide the MK-0482 plasma concentration by two after reaching pseudo-equilibrium. Blood samples were collected pre-dose and post-dose at designated timepoints to determine t½ of MK-0482.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \[Q3W\]) for up to 35 cycles (approximately 24 months).
    id
    OG000
    title
    MK-0482 7.5 mg Q3W
  2. description
    Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
    id
    OG001
    title
    MK-0482 25 mg Q3W
  3. description
    Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
    id
    OG002
    title
    MK-0482 75 mg Q3W
  4. description
    Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
    id
    OG003
    title
    MK-0482 225 mg Q3W
  5. description
    Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).
    id
    OG004
    title
    MK-0482 750 mg Q3W
param Type
GEOMETRIC_MEAN
population Description
All allocated participants who received at least 1 dose of study intervention, were compliant with the study procedures, and had available data from at least 1 treatment dose were analyzed.
reporting Status
POSTED
time Frame
Cycle 1: Pre-dose and Days 1, 2, 4, 8, and 15 post-dose. Cycle=21 days.
title
Plasma Elimination Terminal Half-life (t½) of MK-0482
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice